Please reload

Recent Posts

Hans Petter Tjeldflaat has joined Biovotec AS as part-time CFO on the 29th of February. Hans Petter has a broad experience from similar positions in s...

Hans Petter Tjeldflaat Joins Biovotec As Part-time CFO

March 3, 2016

1/1
Please reload

Featured Posts

A study was conducted using a diabetic mouse model - a recognised, and widely used, animal model of delayed wound healing - and performed at an internationally recognized reference lab. The healing response of wounds treated was compared against human growth factors as positive control.

The healing progress exceeded initial expectations with over 90% wound closure after only 16 days. The results prove to be very encouraging and is seen as a major achievement both by the company and experts in the field. With these obtained results Biovotec is now entering the phase of final product formulation for human trials with the aim to become the standard care for ‘delayed healing wounds’.

 

 

Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags
Please reload

Archive
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Engebrets vei 3, 0275 Oslo, Norway                                                   © Biovotec AS                                                                       info@biovotec